How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion.

The deal also helps accelerate a move into diagnostics by Exact Sciences Corp. (NASDAQ:EXAS), whose revenues have long been tied to its lone marketed colorectal cancer screen, Cologuard.